Wells Fargo on BLUE : Releases Positive KarMMa Results For bb2121 (partner BristolMyers Squibb (BMY | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1125 of 1475  at  12/7/2019 5:59:58 PM  by

Rob Cos


Wells Fargo on BLUE : Releases Positive KarMMa Results For bb2121 (partner BristolMyers Squibb (BMY))

 

Wells Fargo

December 6, 2019 | Equity Research

Flash Comment

Biotechnology

BLUE : Releases Positive KarMMa Results For bb2121

Sector Rating: Biotechnology, Overweight

We are reiterating our OUTPERFORM rating on shares of bluebird bio (BLUE) following release of positive data from the pivotal phase 2 KarMMa study of BCMA CART therapeutic idecel (bb2121) In relapsed/refractory myeloma. We believe that breadth, depth and duration of response are at the high end of expectations, unprecedented in patients triple refractory to iMID/PI/antiCD38 and supportive of a significant commercial opportunity. Relative to approved CART therapeutics we believe that safety compares favorably, in terms of severe cytokine release syndrome (CRS) and neurotoxicity (NT), with only 1 patient death, inline with that seen with YESCARTA in fewer treated patients. We believe that BLUE is undervalued relative to opportunity from its LentiGlobin gene therapy and estimate an incremental NPV of $64/share for idecel. Bluebird bio (BLUE) and partner BristolMyers Squibb (BMY) announces positive phase 2 KarMMa results for BCMA CART therapeutic idecel (bb2121) In relapsed/refractory myeloma. With 140 patients enrolled and 128 treated across 3 dose groups of 150MM cells, 300MM cells and 450MM cells the study met its primary and key secondary endpoints. Key efficacy results included overall response rate (ORR) of 73.4% and complete response rate (CR) of 31.3%, with ORR of 81.5% and CR rate of 35.2% at the highest target dose. Median duration of response (DOR) of 10.6 months, and 11.3 months at the highest dose, was inline with prior phase 1 CRB401 results, with PFS of 11.3 months at the highest dose. Safety was inline with prior CRB401 results with 5.5% grade 3/4 CRS and 3.1% grade 3/4 NT with no grade 4 NT. Only 1 fatal CRS advent occurred. Based on these results BMY and BLUE are preparing regulatory submissions for approval in US and other territories.

bluebird bio, Inc. (BLUE)/Outperform (1)

Price as of 12/6/2019: $79.42

FY 19 EPS: $13.86

FY 20 EPS: $8.77

Shares Out.: 55.3 MM

Market Cap.: $4,391.93 MM

Rating Basis Information:

BLUE Thesis: Lentiglobin gene therapy opportunities in Beta Thalassemia and

Sickle Cell Disease (SCD) should be realized as profound patient benefits seen

with earlier patients are maintained and broadened to more patients. While

concerns have emerged regarding individual patient variability we believe that

more patients than not will benefit from LentiGlobin gene therapy.



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 5     Views: 233
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...